Pfizer Deal With Teva Allows For Entry Of Generic Ellence Ahead Of Patent Expiry
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva will pay $70 mil. to Pfizer to resolve patent litigation over generic versions of Zithromax and Idamycin.
You may also be interested in...
Pfizer Citizen Petition Calls For Recall Of Zithromax Generics
Company also files patent litigation against generic azithromycin manufacturers Teva and Sandoz.
Pfizer’s Zithromax Gets Generic Competition Following ANDA Approvals
Teva, Sandoz and Pliva receive FDA clearance for azithromycin; Greenstone launches authorized generic.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.